Sample NAPLEX Question 2
A 66-year-old female with type 2 DM and a history of MI
one year ago comes in for a follow-up evaluation and reports taking atorvastatin 80 mg daily
without adverse effects. Her pertinent
labs are: A1c = 7.3%, TC = 210 mg/dL, HDL = 40
mg/dL, LDL = 74 mg/dL, TG = 480 mg/dL. Which
of the following is recommended to decrease her CVD risk further?
- Vascepa 2 gm BID
- Lovaza 2 gm BID
- Niaspan 1 gm HS
- Tricor 48 mg daily
Answer: A
Rationale:
- Vascepa (icosapent ethyl) added to statin therapy in
patients with moderately elevated TG (135-499 mg/dL) demonstrated a reduction
in a composite of CV death, nonfatal MI, nonfatal stroke, coronary
revascularization, or unstable angina in the REDUCE-IT trial.
- Lovaza does not have clinical trial evidence to
demonstrate a reduction in CV events in combination with statins.
- Niaspan has not demonstrated additional CV benefit in
patients with controlled LDL (AIM-HIGH was stopped early for lack of benefit).
- Fibrates combined with statins have demonstrated
an increased risk for elevated LFTs and risk of rhabdomyolysis without a
consistent reduction in CV events (possibly a benefit in men).
High-Yield Core Concept:
- Vascepa (icosapent ethyl) can be considered for patients
meeting LDL goals with mild TG elevations to reduce CV risk.
High-Yield Fast Fact(s):
- EPA and DHA are both omega-3 fatty acids.
References:
- Diabetes Care 2020;43(Suppl. 1):S1-S212.
- N Engl J Med 2019;380:11-22.